Traumeel is a compound that is utilized by a wide variety of healthcare practitioners to treat inflammatory states. It is utilized extensively in Germany for multiple inflammatory conditions. The purpose of this document is to review and critique publications written about Traumeel and Traumeel S, a proprietary formulation. Furthermore, this review will determine if the literature supports substituting Traumeel for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids or if adding Traumeel to NSAID and corticosteroid treatment protocols benefits patients with inflammation. Long-term use of NSAIDs and corticosteroids causes significant pathology leaving many patients without an effective treatment to manage their inflammatory condition. Traumeel does not have the severe side effect profile of NSAIDs and corticosteroids. There are important implications of the studies included in this review. The literature supports Traumeel as an effective alternative to NSAIDS and corticosteroids in preventing stomatitis for patients undergoing chemotherapy. Traumeel also provides pain-free outcomes following musculoskeletal and tissue injuries.
Introduction
Traumeel is a compound that is utilized by a wide variety of healthcare practitioners to treat inflammatory states within the body. It is composed of various natural plant and mineral extracts, which target the inflammatory pathways fol-Pharmacology & Pharmacy lowing soft-tissue injury. In the United States, the current mainstay of treatment for inflammatory states due to various conditions consists of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) [1] . Although highly effective, these medications have side effects that limit both their short and long term use in many patients [2] . The purpose of this comprehensive literature review is to present and critique publications written about Traumeel's use for treating patients with a variety of inflammatory conditions. This review also attempts to determine if the literature supports the substitution of Traumeel for NSAIDs and corticosteroids or the use of Traumeel in conjunction with these medications for treatment of certain inflammation conditions.
Background
Inflammation is the physiological and pathological response to cell injury, which results in the recruitment of leukocytes and plasma proteins to affected tissue and activation of tissue-resident macrophages causing para-inflammation [3] .
The inflammatory response is beneficial in many instances, such as bacterial infection and traumatic tissue injury. If the process becomes unregulated, however, the inflammatory response that normally destroys and eliminates pathogens is also capable of injuring normal tissues [4] . First line management of an unregulated inflammatory response is to limit excessive inflammation [5] .
While there are many types of insults that lead to an inflammatory response (i.e. bacterial infections and allergic reactions), this review focuses on the treatment of inflammation caused by musculoskeletal injuries and damage to mucosal membranes. The literature search revealed a paucity of quality research, which limits the scope of this review.
Acute inflammation caused by musculoskeletal injuries often leads to pain, joint instability and loss of function [6] . Conventional management of musculoskeletal injuries involves limiting pain, minimizing further tissue injury, restoring range of motion and improving voluntary muscle control [7] . First-line management is achieved via the rest, ice, compression, and elevation (RICE) protocol, which aims to reduce injury-related bleeding into muscle tissue.
Another pathologic inflammatory condition, mucositis, is a breakdown of mucosal membranes at any location along the gastrointestinal tract. Mucositis is experienced by up to 40% of cancer patients who receive 5-flurouracil for chemotherapy and radiation therapy [8] . Those patients receiving 5-flurouracil experience moderate to severe mucositis, while 10% -15% have severe mucositis which limits the patient's ability to tolerate solid food and liquids [9] .
Currently, the most prescribed treatment for inflammation secondary to mucositis relies on the use of corticosteroids in the oral, injection and topical forms as well as orally administered NSAIDs.
Corticosteroids have been shown to cause hyperglycemia, electrolyte disturbances, hypertension and hematologic abnormalities [10] . Prolonged use of corticosteroids can lead to suppression of the hypothalamic-pituitary-adrenal axis, Low doses of NSAIDs provide therapeutic benefit with a high safety index when used in the acute setting. Deleterious side effects of NSAIDs include heart attack, stroke, peptic ulcers, gastrointestinal bleeding, and kidney disease. Current limitations of these medications and their side effect profiles warrant an effective, safer and better-tolerated medication [13] .
When assessing and weighing the benefits of the myriad of treatment regimens, it is imperative to consider patient preferences. It has been shown that clinical outcomes and patient compliance are significantly impacted when patients have their preferences discussed and honored [14] . Elements which influence a patient's preference include time to onset of pain relief, symptom recurrence, route of administration, consistency, and side effects of the treatment [15] . As traditional treatment regimens may be ineffective or cause unwanted side effects, patients often prefer alternative regimens [16] . Current trends demonstrate that complementary and alternative medicine regimens are being used more frequently [17] . Many studies show that patients prefer a combination of both standard of care therapy and complementary medicine measures rather than a single regimen alone.
Traumeel, Current Use
Traumeel is currently used worldwide for the treatment of inflammatory pathologies and is available in oral, topical, and injection forms [18] . Traumeel S is a specific formulation that contains highly diluted extracts of plants and minerals including Arnica montana, Calendula officinalis, Achillea millefolium, Matricaria chamomilla, Symphytum officinale, Atropa belladonna, Aconitum napellus, Bellis perennis, Hypericum perforatum, Chinacea angustfolia, Echinacea purpurea, Hamamelis virginica, Mercurius solubilis and Hepar sulfuris (Table   1 ). Traumeel S is manufactured by the HEEL Company in Baden-Baden, Germany and follows the European Union guidelines for manufacturing practice for medicinal products [19] . The product has been available as an over the counter therapy in Germany, Australia, and Switzerland for the past 50 years.
Traumeel S is used across Western Europe to treat inflammation caused by joint sprains, epicondylitis, arthroses, contusions, bursitis, and hematomas. The literature search identified studies focusing on Traumeel in the treatment of musculoskeletal injuries compared to corticosteroid and NSAID treatments.
Additional studies have been conducted in the setting of chemotherapy-induced mucositis as both a preventative option and a treatment option [20] . There is evidence that Traumeel is involved in the microbiologic biochemical pathways regarding inflammation. While reducing acute inflammation similar to NSAIDS, Traumeel does not affect granulocyte function or human platelet adhesion in vitro [22] . There is evidence to suggest that Traumeel accelerates the healing process rather than inhibiting edema development directly. Interestingly, Traumeel has been studied for its role in increasing the production of transforming growth factor beta (TGF-β), thus increasing the production of regulatory lymphocytes [23] . Through TGF-β production, other inflammatory cytokines including IL-1 and TNF-α are prevented from up-regulating the inflammatory process [24] . Traumeel has also been studied for its indirect role regarding its inhibition of NK-kB and the activation of inflammatory cytokines [25] . 
Methods for Literature Search

Results
Oberbaum et al. for all five evaluated variables in both treatment groups. Patients in the Traumeel S group showed greater improvements in pain at rest and changes in extensional and torsional joint mobility when compared to the NSAID group. Both patient groups rated the treatment as "very good" and "good" and 87.7% of patients in the Traumeel S group rated the tolerability as "very good" compared to 44.9% in the NSAID group. In terms of differences among treatment groups, because the groups were highly similar, the adjustment using the propensity score had no influence on the evaluation of respective treatments. As a non-inferiority study to compare the efficacy of Traumeel S with standard NSAID therapy in the treatment of epicondylitis, the results concluded that Traumeel S is equivalent to NSAIDs in all variables for the short-term, localized treatment of epicondylitis and may be a suitable alternative to NSAIDs due to its high tolerability profile. As an observational cohort study, there was possibility for large differences between treatment groups. This was accounted for via propensity score analysis to balance observed co-variates. Additionally, the subjective nature regarding the terminology of describing treatment as "satisfactory," "good," and "very good," must be considered when interpreting the study results. A conflict of interest may also be represented in this study due to its funding by Biologische Heilmittel Heel, GmbH, the manufacturer of Traumeel.
A controlled, double blind study performed by Bohmer et al. aimed to compare and assess the effectiveness of commercially available Traumeel S ointment and Traumeel ointment which containing only six constituents versus a placebo.
The study contained 102 healthy patients between the ages of 18 -50 with visible or palpable tissue alterations only requiring outpatient treatment. Participants were divided into three comparable groups. The primary endpoints were regression of swelling measured on day one, five, and 15 and reduction of skin temperature, both measured and compared with the uninjured contralateral side.
Secondary effectiveness criteria were indicated as increased maximum muscle force, reduction of pain intensity, and time required to return to physical training. Patients received the first treatment no more than four days following the initial injury and applied the medication twice daily for the following 15 days.
Both Traumeel groups were found to be superior to placebo in reduction of swelling after 15 days with a significance of p < 0.0067; however, no significant patients evaluated for periodontal status using Russell's periodontal index and a control group of 22 patients with healthy periodontal tissues. Blood was collected from both sets of patients and analyzed for nitro blue tetrazolium (NBT) reduction in blood, plasma and serum using spectrophotometry. There was a statistically significant elevation in leukocyte count in the periodontitis group when compared to the control group with a p-value < 0.05. The antioxidant capacity of blood plasma was significantly higher in the periodontitis group when compared to the control group, but the antioxidant capacity of serum was lower with a statistical significance of p < 0.05. Traumeel S was not found to have any effect on the antioxidant capacity within either group. This study had a The results of each individual study are summarized below (Table 2) . 
Conclusions
There are many important implications of the studies included in this review.
Traumeel S is an effective alternative to NSAIDs and corticosteroids in pre- There is a poverty of sources that have examined clinical outcomes comparing Traumeel and NSAIDs. Further studies would be helpful in order for stronger conclusions about Traumeel's potential for inflammation to be discovered.
In conclusion, the literature reviewed in this manuscript identifies Traumeel as a potential mainstay of treatment for inflammation with minimal side effects as compared to current medical regimens. However, further investigations of Traumeel are warranted to identify mechanism of action, best route of administration, and most effective treatment regimen.
